In this article, we will take a look at the 10 Best US Stocks to Buy Under $50.
Volatility is on the rise amid a return to tariff-fuelled market pullbacks. Major US indices are on the back foot early in the year as US President Donald Trump reignites trade war tensions with Europe over renewed friction to take control of Greenland.
Bridgewater Associates founder Ray Dalio has already warned that President Trump’s aggressive political direction could spark a new phase of global financial conflict as investors reconsider their appetite for US assets.
“On the other side of trade deficits and trade wars, there are capital and capital wars,” Dalio told CNBC’s “Squawk Box” at the World Economic Forum in Davos, Switzerland. “If you take the conflicts, you can’t ignore the possibility of the capital wars. In other words, maybe there’s not the same inclination to buy at U.S. debt and so on.”
A bull run that has been on a roll for over three years is at risk as investors increasingly consider taking profits and getting out of equities trading at above historical norms. A spike in the so-called sell America trade comes on the back of a spike in US treasury yields and a slump in the US dollar. The selloff comes amid Trump’s threat to impose 200% tariffs on European products.
“It’s not a major pullback yet, and so we do think there’s a possibility and a very realistic possibility for things to go perhaps a more negative turn before they get better, and that’s something that investors could want to position for,” Yung-Yu Ma, chief investment strategist at PNC Asset Management, said Tuesday on CNBC’s “Closing Bell.”
The pullback comes as Deutsche Bank reiterates that this could be one of the most challenging years for artificial intelligence, amid market demand for tangible returns from the revolutionary technology. Analyst Adrian Cox predicts that while Silicon Valley and astute early adopters continue to see the technology’s advantages, AI will experience a phase of disillusionment.
Amid the expected rotation and pullback in the US equity market, there are stocks likely to remain resilient and continue edging higher, supported by the expected easing of monetary policy. With that in mind, let’s take a look at some of the best US stocks to buy under $50.
Source: Unsplash
Our Methodology
To determine the Best US Stocks to Buy Under $50, we used the Finviz screener and shortlisted stocks trading for less than $50. We trimmed the list further by focusing on stocks with upside potential of more than 50% and a Strong Buy rating. Finally, we ranked the stocks in ascending order by the number of hedge funds holding stakes in them as of the third-quarter of 2025.
Note: All data was sourced on January 22.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research shows we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
Best US Stocks to Buy Under $50
10. VinFast Auto Ltd. (NASDAQ:VFS)
Stock Price: $3.38
Stock Upside Potential: 70.07%
Number of Hedge Fund Holders: 7
VinFast Auto Ltd (NASDAQ:VFS) is one of the best US stocks to buy under $50. On January 6, VinFast Auto Ltd (NASDAQ:VFS) confirmed that it achieved the highest annual delivery volume in Vietnam. The company delivered 175,099 vehicles in 2025, with the VF3 and VF5 emerging as the bestselling models in the country.
The company delivered 44,585 VF3 and 43,913 VF5 models in the year, supplemented by 27,127 Limo Green vehicles, 23,291 VF6 vehicles, 12,568 Herio Green vehicles, and 9,653 VF7 vehicles. The preliminary figures represent nearly double the number of deliveries the company made in the country in 2024. It also underscores the strong growth in the company’s core market even as it faces challenges overseas.
VinFast has struggled to achieve success in North America and other international markets amid stiff competition and slow consumer adoption. Nevertheless, in Vietnam, the company benefits from strong brand recognition and a growing domestic demand for electric vehicles. It also enjoys strong support from parent conglomerate Vingroup.
Meanwhile, Chardan Capital analyst James Mcllree has reiterated a Buy rating on the stock and set a $5.50 price target.
VinFast Auto Ltd. (NASDAQ:VFS) is a Vietnamese electric vehicle (EV) manufacturer, part of Vingroup, focused on designing and producing smart electric cars, e-scooters, and electric buses for global markets, aiming to make EVs accessible with premium features, advanced tech, and sustainable mobility solutions.
9. Bitdeer Technologies Group (NASDAQ:BTDR)
Stock Price: $14.51
Stock Upside Potential: 116.88%
Number of Hedge Fund Holders: 26
Bitdeer Technologies Group (NASDAQ:BTDR) is one of the best US stocks to buy under $50. On January 16, analysts at BTIG reiterated a Buy rating on Bitdeer Technologies Group (NASDAQ:BTDR) and set a $25 price target.
The research firm remains confident about the company’s prospects, having raised its 2025 revenue estimates to $615 million from an initial projection of $588 million. It also expects 2026 revenue to reach $1.1 billion, an improvement from its initial guidance of $1 billion. Likewise, the research firm expects the company to deliver EBITDA of about $374 million.
Analysts at Rosenblatt Securities have also reiterated a Buy rating on the stock with a $30 price target, impressed by the company’s productive December performance. During the month, the company increased its Bitcoin mining output by 21% as it expanded the deployment of its generation mining rig, Sealminer A3, to 5.9 EH/s from 0.6 EH/s in November. Rosenblatt has also touted the company’s prospects as it converts an additional 225MW capacity to support AI applications.
Bitdeer Technologies Group (NASDAQ:BTDR) is a global tech company specializing in Bitcoin mining and AI cloud services, offering end-to-end solutions including datacenter management, hash rate sharing, and proprietary mining, while also expanding into robust AI infrastructure with NVIDIA GPUs for advanced computing workloads.
8. Legend Biotech Corporation (NASDAQ:LEGN)
Stock Price: $19.13
Stock Upside Potential: 197.11%
Number of Hedge Fund Holders: 28
Legend Biotech Corporation (NASDAQ:LEGN) is one of the best US stocks to buy under $50. On January 15, analysts at Deutsche Bank reiterated a Buy rating on Legend Biotech Corporation (NASDAQ:LEGN) and set a $60 price target. The positive stance comes amid expectations that the company will deliver topline results from its first in-vivo CAR T program for patients before the end of the year.
Initial preclinical data have already shown robust dose-dependent CAR-T expansion in non-human primates. The data have also demonstrated sustained peripheral B-cell elimination from day 8 to day 36. The data suggest that in vivo CAR-T cells exhibit properties similar to those of traditional CAR-T treatments.
Amid the expected positive clinical trial results, Legend Biotech has also reiterated plans to achieve profitability in 2026. Profitability would come even as the company focuses on developing its pipeline, focusing on in vivo and allogeneic CAR-T therapies.
Similarly, Cantor Fitzgerald has also reiterated its bullish stance on the stock. On December 17, the research firm reaffirmed an Overweight rating on the stock and a $74 price target. According to the research firm, the company’s cancer therapy, Carvykti, is on track to deliver a 100% year-over-year increase in sales to $2 billion. The company’s partner, Johnson & Johnson, expects Carvykti’s peak sales to exceed $5 billion in the rapidly growing multiple myeloma market.
Legend Biotech Corporation (NASDAQ:LEGN) is a global clinical-stage biotechnology company focused on discovering, developing, and commercializing novel cell therapies, primarily for cancer (oncology) and other severe diseases. It leverages technologies such as CAR-T cell therapy to create personalized treatments, including its successful CARVYKTI for multiple myeloma, and works with partners such as Johnson & Johnson.
7. Super Group (SGHC) Limited (NYSE:SGHC)
Stock Price: $9.63
Stock Upside Potential: 78.57%
Number of Hedge Fund Holders: 31
Super Group (SGHC) Limited (NYSE:SGHC) is one of the best US stocks to buy under $50. On January 21, Super Group (SGHC) Limited (NYSE:SGHC) reported strong fourth-quarter and full-year 2025 results and announced a $0.25 special dividend. Casino performance remained a key driver of profitability, while sports outcomes in December lowered hold to its weakest level since October 2023. Despite this, the company hit record highs in active customers and deposits, underscoring solid demand.
Super Group expects full-year revenue of $2.17–$2.27 billion and adjusted EBITDA of $555–$565 million, with growth momentum carrying into 2026. CEO Neal Menashe highlighted the company’s resilient operating model and strong balance sheet, noting that the dividend reflects confidence in long-term value creation and continued expansion.
On January 22, Citizens reiterated its Market Outperform rating on SGHC Limited with a $16 price target, noting that the company’s fundamentals remain strong despite recent unfavorable sports outcomes, which it views as a temporary setback. With more cash than debt and a very low debt-to-equity ratio of 0.1, SGHC’s financial health supports confidence in its long-term outlook. Citizens kept its 2026 and 2027 estimates unchanged, projecting a 14% EBITDA increase in 2026, backed by growth initiatives and already accounting for UK gaming taxes and sports-related impacts.
Super Group (SGHC) Limited (NYSE:SGHC) is a holding company for global online sports betting and gaming businesses, primarily operating through its Betway and Spin brands. It offers gaming and casino products across Europe, the Americas, and Africa.
6. Viking Therapeutics, Inc. (NASDAQ:VKTX)
Stock Price: $32.90
Stock Upside Potential: 189.38%
Number of Hedge Fund Holders: 37
Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best US stocks to buy under $50. On January 12, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced a significant milestone in the development of its obesity drug VK2735.
Data published in the peer-reviewed journal Obesity show that the drug achieved a weight loss of 14.7% from baseline after 13 weeks of treatment, with no plateau observed. The clinical trial also met both primary and secondary endpoints. Following the positive Phase 2 trials, Viking is evaluating VK2735 in the Phase 3 VANQUISH-1 trial. It has already enrolled about 4,650 patients.
“The study data served to highlight the promise that VK2735 holds as a potentially best-in-class dual GLP-1/GIP agonist and were central to our designing of the ongoing VANQUISH Phase 3 program,” said Brian Lian, CEO of Viking Therapeutics.
The positive clinical trials come as interest in weight loss drug deals remains strong in the market. According to Viking Therapeutics CEO Brian Lian, drug makers are increasingly seeking ways to tap into the potential $150 billion market.
Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharma company developing drugs for metabolic and endocrine diseases, notably obesity, fatty liver (MASH), and rare conditions.
5. Vaxcyte Inc. (NASDAQ:PCVX)
Stock Price: $49.75
Stock Upside Potential: 124.94%
Number of Hedge Fund Holders: 46
Vaxcyte Inc. (NASDAQ:PCVX) is one of the best US stocks to buy under $50. On January 23, Cantor Fitzgerald reaffirmed its Overweight rating on Vaxcyte Inc. (NASDAQ:PCVX), keeping a positive view as the company advances its vaccine pipeline on schedule. The firm expects topline results from the Phase 3 OPUS-1 trial in late 2026, with an adult BLA filing planned for 2027.
It also noted progress in other studies: OPUS-2 has started dosing, OPUS-3 will begin in early 2026, and both should report results in 2027. Meanwhile, the infant Phase 2 VAX-31 study is on track, with key readouts expected by mid-2027.
Earlier on January 6, Evercore ISI reiterated an Outperform rating on Vaxcyte Inc., impressed by the CDC’s changes to childhood vaccination recommendations.
The positive stance comes from the CDC removing blanket recommendations for several vaccines, including Flu, COVID-19, and Hepatitis B. In addition, recommendations for childhood vaccinations, such as measles, polio, tetanus, and HPV, among others, remain in place.
The company is well-positioned to benefit, as it is also developing pneumococcal conjugate vaccines (PCVs). That’s because vaccine-sceptic groups and the CDC have yet to target pneumococcal vaccines.
Meanwhile, Jefferies maintains a Buy rating on the stock with a $146 price target. The research firm has echoed the company’s prospects amid the Phase 3 VAX-31 adult trial. Designed to protect against 31 types of Streptococcus pneumonia, VAX 31 has already delivered topline results in Phase ½ clinical trials.
Vaxcyte Inc. (NASDAQ:PCVX) has already met non-inferiority and superiority endpoints in the trials, thus on course to become the new standard for adult pneumococcal vaccination and consolidate market share against competing vaccines.
4. Waystar Holding Corp. (NASDAQ:WAY)
Stock Price: $29.58
Stock Upside Potential: 57.31%
Number of Hedge Fund Holders: 47
Waystar Holding Corp. (NASDAQ:WAY) is one of the best US stocks to buy under $50. On January 16, analysts at BofA Securities reiterated a Buy rating and a $52 price target on Waystar Holding Corp. (NASDAQ:WAY). According to the research, the company is well-positioned to benefit as customers plan to replace and spend more on the revenue cycle.
The fact that 74% of hospitals don’t plan to change their revenue cycle vendors asserts the company’s outlook. That’s because it is an improvement from 60% as of the third quarter of last year.
Similarly, Wells Fargo initiated coverage of the stock with an Overweight rating and a $41 price target on January 9. According to the research firm, Waystar is a “rule-of-50 compounder with predictable, high-margin growth.”
While more than two-thirds of the company’s revenue comes from the ambulatory segment of the healthcare industry, the company dominates a fragmented market that competitors find difficult to penetrate. Likewise, the expanding reach of the company’s services segment represents a growing competitive edge.
Waystar Holding Corp. (NASDAQ:WAY) provides cloud-based software for healthcare organizations to simplify and automate the entire revenue cycle, from patient scheduling and insurance verification to billing, claims management, and payment collection, using AI and automation to improve accuracy, reduce costs, and speed up reimbursements for providers.
3. TeraWulf Inc. (NASDAQ:WULF)
Stock Price: $13.58
Stock Upside Potential: 64.86%
Number of Hedge Fund Holders: 47
Terawulf Inc (NASDAQ:WULF) is one of the best US stocks to buy under $50. On December 18, Terawulf Inc (NASDAQ:WULF) secured financing for a 168 MW high-performance computing facility in Texas. The funding is part of a long-term credit enhancement provided through the Fluidstack platform.
The company plans to develop a next-generation liquid-cooled AI data center delivering 240MW of gross power capacity. Its development underlines TeraWulf’s evolution as it moves to capitalize on sustained high-performance computing demand. Consequently, the company plans to expand the capacity of the initial 168MW phase while leveraging existing transmission land and development infrastructure.
“This financing represents another important step in scaling a platform that was designed from the outset to grow,” said Paul Prager, Chief Executive Officer of TeraWulf. “We focused early on building sites, relationships, and structures that could adapt as the AI market evolved. Today’s environment validates that approach.”
TeraWulf Inc. (NASDAQ:WULF) develops and operates sustainable, zero-carbon data centers for Bitcoin mining and high-performance computing (HPC), including AI workloads, providing digital infrastructure that integrates advanced technology with renewable energy sources such as nuclear, hydro, and solar.
2. Klaviyo Inc. (NYSE:KVYO)
Stock Price: $25.92
Stock Upside Potential: 74.77%
Number of Hedge Fund Holders: 48
Klaviyo Inc. (NYSE:KVYO) is one of the best US stocks to buy under $50. On January 12, Cantor Fitzgerald reiterated an Overweight rating on Klaviyo Inc. (NYSE:KVYO) and a $40 price target. The bullish stance comes as the research firm does not expect artificial intelligence to take over the software world.
Cantor Fitzgerald does not expect enterprises to reinvent the wheel amid the artificial intelligence revolution, given the complexity of existing features and workflows. Consequently, it remains confident in the company’s position amid developments in AI in the software industry.
The research firm expects the launch of Marketing Agent and Customer Agent products to strengthen the company and drive significant upside in 2026. Revenue is expected to surpass $1 billion, up 32.8% over the past 12 months. Cantor Fitzgerald remains bullish about the company’s prospects, given its leading position in the software-as-a-service market.
Meanwhile, BTIG has also touted Klaviyo as one of its best stock picks for the first half of the year. Analyst Nick Altman has a $40 price target on the stock in anticipation of a significant upswing on the formation of a double bottom.
Klaviyo Inc. (NYSE:KVYO) is a technology company that provides an AI-powered B2C Customer Relationship Management (CRM) platform that unifies marketing, service, and analytics for e-commerce brands.
1. Grab Holdings Limited (NASDAQ:GRAB)
Stock Price: $4.58
Stock Upside Potential: 59.32%
Number of Hedge Fund Holders: 59
Grab Holdings Limited (NASDAQ:GRAB) is one of the best US stocks to buy under $50. On January 19, BofA Securities upgraded Grab Holdings Limited (NASDAQ:GRAB) to a Buy from a Neutral and reiterated a $6.30 price target. The upgrade comes on the heels of the stock underperforming, as it has slumped 32% since September.
Amid the underperformance, BofA Securities insists the company’s fundamentals in core mobility and deliveries remain strong. In addition, the company is facing minimal competition, backed by stable and improving margins that justify the upgrade. Consequently, the research firm expects Grab Holdings gross merchandise value to grow at a compound annual growth rate of 17% between 2024 and 2027.
Additionally, the firm expects the company’s adjusted EBITDA margin as a percentage of GMV to improve to 5.5% by 2027 from 3.6% as of 2024. The $5 billion net cash position is also seen as a positive, helping limit downside risk amid expected strong performance in GrabMart or quick commerce operations.
Meanwhile, on January 6, Grab announced it would strengthen its first- and last-mile delivery capabilities through the acquisition of China-based Infermove, a developer of AI-enabled robotics solutions. It plans to leverage Infermove’s autonomous robots to enhance customer experiences.
Grab Holdings Limited (NASDAQ:GRAB) is a tech giant operating a super app that provides ride-hailing, food/grocery delivery, GrabFood, GrabMart, package delivery, GrabExpress, and digital financial services, GrabPay, lending, and insurance, all in one platform, connecting consumers with driver-partners, merchants, and delivery partners for everyday needs.
While we acknowledge the potential of GRAB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GRAB and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 8 Best Stocks to Buy According to Billionaire Bill Ackman and 10 Best Cheap Stocks That Will Skyrocket.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
